Form 4/A for DCOY Decoy Therapeutics Inc.
Accepted 2022-12-12 00:00:00 ET · period of report 2022-11-03 · accession 0001615219-22-000155 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-12-12 | 2022-11-03 | DCOY | Arthur David J. | CEO, Dir | A - Grant | $1.73 | +2,693 | 13.7K | +24% | +$4,659 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-03 | A | A | 2,693 | $1.73 | 13,719 | D | — | — | (F1) The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 10,000 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 2,693 shares of common stock. |